Twist Bioscience Corporation Common Stock TWST

Twist Bioscience Corporation es una empresa de biología sintética y genómica. La Compañía ha desarrollado una plataforma de síntesis de ADN de Twist Bioscience para industrializar la ingeniería de la biología. El núcleo de su plataforma es una tecnología que proporciona un nuevo método de fabricación de ADN sintético escribiendo ADN en un chip de silicio. La Compañía utiliza su tecnología para fabricar una variedad de productos basados en ADN sintético, incluyendo genes sintéticos, herramientas para la preparación de secuenciación de próxima generación (NGS) y bibliotecas de anticuerpos para el descubrimiento y desarrollo de medicamentos. Consta de dos líneas de productos, herramientas de biología sintética y herramientas de NGS, que abordan diferentes necesidades de sus clientes en una variedad de aplicaciones, como genes sintéticos, piscinas de oligos, herramientas SARS-CoV-2 y bibliotecas de ADN. Sus productos de biología sintética incluyen genes y fragmentos de genes sintéticos, oligonucleótidos o piscinas de oligos para la edición de genes CRISPR. Los productos de NGS se utilizan para pruebas diagnósticas para diversas indicaciones como SARS-CoV-2.

• GlobeNewswire Inc. 5 oct

  Global Oligonucleotide Synthesis Reagents Market Size, Share, and Forecast, 2026-2033 | Therapeutics Demand Fuels 11.9% CAGR and USD 1.75 Billion Opportunity

  The global oligonucleotide synthesis reagents market is valued at USD 723.3 million in 2025 and is projected to reach USD 1.75 billion by 2033, growing at a 11.9% CAGR. Growth is driven by increasing demand for nucleic acid-based therapeutics including siRNA, antisense oligonucleotides, CRISPR gene editing, and mRNA platforms across oncology, rare genetic disorders, and infectious diseases.

  

• The Motley Fool 18 sept

  Why Twist Bioscience Stock Skyrocketed This Week

  Twist Bioscience stock surged over 31% this week after announcing a partnership with Eli Lilly to participate in Lilly TuneLab, an AI-powered drug discovery initiative. Twist will provide antibody characterization data services and leverage its AbLab model, generating revenue while contributing to and benefiting from the advanced research platform.

  

• The Motley Fool 19 jul

  Cathie Wood Is Selling This High-Flying Stock. Is It a Buy?

  Cathie Wood's Ark ETFs sold over $11 million worth of Twist Bioscience stock on June 30, 2026, despite the synthetic DNA manufacturer's stock climbing 190% year-to-date. The sales appear to be portfolio rebalancing rather than a loss of confidence, as Ark still holds over $332 million in Twist across its ETFs. The proceeds were used to purchase stakes in other companies like Circle Internet Group and SoFi Technologies.

  

• The Motley Fool 19 jun

  The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Own

  The next wave of AI adoption is shifting from tool-builders to companies applying AI in real-world drug development. Eli Lilly leverages AI partnerships with OpenAI and Nvidia for drug discovery while expanding its weight-loss portfolio, showing strong financial growth. Twist Bioscience supplies synthetic DNA for drug testing and benefits from Amazon's new Bio Discovery platform, offering higher-risk growth potential.